Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.

导出原文传递

翻译打印收藏纠错

作者： Ying,Chen ^[1] ; Sandra Catalina,Camacho ^[1] ; Thomas R,Silvers ^[1] ; Albiruni R A,Razak ^[2] ; Nashat Y,Gabrail ^[3] ; John F,Gerecitano ^[4] ; Eva,Kalir ^[1] ; Elena,Pereira ^[5] ; Brad R,Evans ^[1] ; Susan J,Ramus ^[6] ; Fei,Huang ^[1] ; Nolan,Priedigkeit ^[1] ; Estefania,Rodriguez ^[1] ; Michael,Donovan ^[7] ; Faisal,Khan ^[7] ; Tamara,Kalir ^[7] ; Robert,Sebra ^[1] ; Andrew,Uzilov ^[1] ; Rong,Chen ^[1] ; Rileen,Sinha ^[1] ; Richard,Halpert ^[8] ; Jean-Noel,Billaud ^[8] ; Sharon,Shacham ^[9] ; Dilara,McCauley ^[9] ; Yosef,Landesman ^[9] ; Tami,Rashal ^[9] ; Michael,Kauffman ^[9] ; Mansoor R,Mirza ^[9] ; Morten,Mau-Sørensen ^[10] ; Peter,Dottino ^[5] ; John A,Martignetti ^[11]

作者单位： Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York. ^[1] Drug Development Program, Princess Margaret Cancer Center, Toronto, Canada. ^[2] Gabrail Cancer Center, Canton, Ohio. ^[3] Memorial Sloan Kettering Cancer Center, New York, New York. ^[4] Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York. ^[5] School of Women's and Children's Health, University of New South Wales, Sydney, New South Wales, Australia. ^[6] Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York. ^[7] Qiagen, Redwood City, California. ^[8] Karyopharm Therapeutics Inc, Natick, Massachusetts. ^[9] Department of Oncology, Rigshospitalet, Copenhagen, Denmark. ^[10] Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York. john.martignetti@mssm.edu. ^[11] Western Connecticut Health Network, Danbury, Connecticut. ^[12]